NASDAQ:FMTX Forma Therapeutics (FMTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$20.01▼$20.0150-Day Range$19.91▼$20.0152-Week Range$4.95▼$20.68Volume1 shsAverage Volume847,595 shsMarket Capitalization$957.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Forma Therapeutics alerts: Email Address Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Forma Therapeutics Stock (NASDAQ:FMTX)Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Read More Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. FMTX Stock News HeadlinesSeptember 25, 2022 | finance.yahoo.comForma Therapeutics Holdings, Inc. (FMTX)September 7, 2022 | finance.yahoo.comBiotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 7, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates GMTX, FMTX, SGFY, ECOMSeptember 7, 2022 | benzinga.comThe M&A Class Action Firm Announces the Investigation of Forma Therapeutics Holdings, Inc. - FMTXSeptember 2, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Forma Therapeutics HldgsSeptember 2, 2022 | seekingalpha.comForma Therapeutics: Rare Disease PlaySeptember 1, 2022 | markets.businessinsider.comNovo Nordisk To Acquire Forma Therapeutics - Quick FactsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 1, 2022 | finance.yahoo.comNovo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disordersSeptember 1, 2022 | marketwatch.comNovo Nordisk to Buy Forma Therapeutics for $1.1 Billion >FMTX NVOSeptember 1, 2022 | apnews.comFMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to ShareholdersSeptember 1, 2022 | finance.yahoo.comForma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billionSeptember 1, 2022 | finance.yahoo.comUPDATE 1-Novo Nordisk to acquire Forma Therapeutics in $1.1. bln dealAugust 11, 2022 | nasdaq.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) up 28%, but insiders miss out having sold stock earlier this yearAugust 3, 2022 | msn.comRigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing PactAugust 2, 2022 | finance.yahoo.comRigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid LeukemiaJuly 29, 2022 | finance.yahoo.comForma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022See More Headlines Receive FMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FMTX CUSIPN/A CIK1538927 Webwww.formatherapeutics.com Phone617-679-1970FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-172,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.68% Return on Assets-35.33% Debt Debt-to-Equity RatioN/A Current Ratio12.74 Quick Ratio12.74 Sales & Book Value Annual Sales$100.56 million Price / Sales9.52 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book1.90Miscellaneous Outstanding Shares47,853,000Free Float45,082,000Market Cap$957.54 million OptionableNot Optionable Beta-0.94 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Frank D. Lee (Age 54)Pres & CEO Comp: $963.2kMr. Todd E. Shegog (Age 56)Sr. VP & CFO Comp: $620.25kDr. John E. Bishop Ph.D. (Age 60)Sr. VP & Chief Technology Officer Dr. David N. Cook Ph.D. (Age 64)Sr. VP & Chief Scientific Officer Mr. Mario Vincent Corso C.F.A.Head of Investor RelationsDr. Jeannette Potts J.D. (Age 60)Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. Ms. Xuandai Nguyen Ph.D.VP of Commercial Strategy & MarketingMs. Linea Aspesi (Age 52)Sr. VP & Chief HR Officer Mr. Brian Lesser (Age 47)Sr. VP of Commercial Dr. Ifeyinwa Osunkwo M.D.M.P.H., Sr. VP & Chief Patient OfficerMore ExecutivesKey CompetitorsSyros PharmaceuticalsNASDAQ:SYRSDenali TherapeuticsNASDAQ:DNLIArcellxNASDAQ:ACLXIovance BiotherapeuticsNASDAQ:IOVASpringWorks TherapeuticsNASDAQ:SWTXView All Competitors FMTX Stock Analysis - Frequently Asked Questions How were Forma Therapeutics' earnings last quarter? Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.05. When did Forma Therapeutics IPO? Forma Therapeutics (FMTX) raised $201 million in an IPO on Friday, June 19th 2020. The company issued 11,800,000 shares at $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse served as the underwriters for the IPO. What other stocks do shareholders of Forma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forma Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), Walt Disney (DIS) and DocuSign (DOCU). This page (NASDAQ:FMTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forma Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.